Orthopedic implant and equipment maker Stryker
During the company's second-quarter conference call, CEO Stephen MacMillan said that Stryker is "clearly on track to deliver a seventh straight year of double-digit sales growth." Total sales improved 16% compared with a year ago, with a 14.6% jump in the implant business on particular strength in spine, knee, and "craniomaxillofacial" implants, which Google tells me are related to dentistry. The medical equipment segment led the way with an 18.3% increase.
Growth was also strong domestically, as sales advanced more than 17% for the quarter. International growth was a bit lower but still healthy at 13.6%, with some assistance from a weak dollar. The end result was an earnings gain of 25%, and the sale of a physical therapy business helped boost operating earnings, which were up by 11.5%.
Stryker's growth was indeed "broad and quite balanced," as MacMillan put it, and he's calling for a 20% overall bottom-line increase for the year. If all goes according to plan, sales growth will come in at 12% to 13%, up from previous company guidance of 11% to 13%.
With the benefit of perfect hindsight, the best time to pick up shares in Stryker and rivals Zimmer
As baby boomers age and look to stay active well into their golden years, they likely will increasingly need new hips, knees, help for their spines, and even craniomax-whatever-you-call-them procedures. That bodes well for all competing in the space, and Stryker should be tops on the list because of its stellar growth and prodigious cash flow.
For related Foolishness:
- Only One Bone to Pick With Stryker
- Read This Before the Market Crashes
- The 10 Signs of a Great Growth Stock
- Why You Should Beat Wall Street
What will they think of next? A free trial of Rule Breakers gives you a chance to chat with other investors and our analysts about the technologies that will change our lives and help our portfolios.
Fool contributor Ryan Fuhrmann has no financial interest in any company mentioned. Feel free to email him with feedback or to discuss any companies mentioned further. The Fool has an ironclad disclosure policy.
More from The Motley Fool
The Top 3 Dividend Aristocrats to Watch in 2018
Big news in the coming year could send these stocks higher or threaten their payouts.
These 3 Stocks Just Raised Their Dividends
There isn't much time left for companies to get in their last payout hikes of 2017. This trio made it with only weeks to spare.
Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today
These stocks helped put downward pressure on the market. Find out why.